Details of the Drug

General Information of Drug (ID: DMVYXFK)

Drug Name
TAK-755
Synonyms ADAMTS13
Indication
Disease Entry ICD 11 Status REF
Congenital thrombotic thrombocytopenic purpura 3B64.14 Phase 3 [1]
Thrombotic thrombocytopenic purpura 3B64.14 Phase 3 [2]
Drug Type
Enzyme replacement
Cross-matching ID
TTD ID
D6PMR7

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
A disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13) TTUREBK ATS13_HUMAN Replacement [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05770219) Expanded Access Program: TAK-755 (rADAMTS13) for the Prophylaxis and Treatment of Severe Congenital or Hereditary Thrombotic Thrombocytopenic Purpura. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT03393975) A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2 Period Crossover Study With a Single Arm Continuation Evaluating the Safety And Efficacy of BAX 930 (rADAMTS13) in the Prophylactic And On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP]). U.S.National Institutes of Health.
3 Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease. Haematologica. 2022 Nov 1;107(11):2650-2660.